The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression.

Abstract

Lung cancer is the major cause of cancer-related mortality worldwide owing to its late-stage detection and aggressive behavior. Epidemiologically, several genetic and epigenetic factors contribute to the development of lung cancer. Angiogenesis, a critical process in tumor progression has become an important target for anti-cancer therapy particularly in lung cancer. Besides commercially available angiogenic inhibitors, numerous anti-angiogenic therapies have been developed to limit tumor growth, although, most of them have not proved beneficial in terms of long-term survival. Despite, logical advances in treatment strategies, NSCLC still remains a major health concern due to poor prognosis of the diseases state. This calls for a comprehensive analysis of signaling processes governing tumor angiogenesis and treatment options available thereof for development of a sustainable strategy to control cancer. In this review, several aspects of lung cancer have been discussed starting from its pathological characterization to the development of modern therapeutics.

• Authors: Qazi Danish, Taseem A Mokhdomi, Shoiab Bukhari, Raies Ahmad
• Journal: Cancer biomarkers : section A of Disease markers (Cancer Biomark) Vol. 15 Issue 5 Pg. 619-33 ( 2015) ISSN: 1875-8592 [Electronic] Netherlands
• PMID: 26406951 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Receptors, Vascular Endothelial Growth Factor

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Disease Progression
• Humans
• Lung Neoplasms (drug therapy, genetics, pathology)
• Neovascularization, Pathologic (drug therapy, genetics, pathology)
• Receptors, Vascular Endothelial Growth Factor (genetics)
• Signal Transduction (drug effects)